CoChat

The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.

Impact of antifibrotic therapy on disease progression, all-cause mortality, and risk of acute exacerbation in non-IPF fibrosing interstitial lung diseases: evidence from a meta-analysis of randomized controlled trials and prospective controlled studies

Open access
Li, De-yu, Liu, Xin, Huang, Jing-yi, Hang, Wen-lu, Yu, Gu-ran, Xu, Yong · 2024 · Therapeutic Advances in Respiratory Disease

Abstract

Background: Nintedanib and pirfenidone are preferred pharmacological therapies for patients with idiopathic pulmonary fibrosis (IPF). However, evidence favoring antifibrotic therapy in patients with non-IPF fibrosing interstitial lung diseases (ILD) is limited. Objective: To investigate the effects of antifibrotic therapy on disease progression, all-cause mortality, and acute exacerbation (AE) risk in patients with non-IPF fibrosing ILDs. Design: Meta-analysis. Data sources and methods: Electronic databases were searched for articles published before 28 February 2023. Studies that evaluated the efficacy of antifibrotic agents in patients with fibrosing ILDs were selected. The primary outcome was the disease progression risk, and the secondary outcomes included all-cause mortality and AE risk. The GRADE criteria were used for the certainty of evidence assessment. Results: Nine studies with 1990 participants were included. Antifibrotic therapy reduced the rate of patients with disease progression (five trials with 1741 subjects; relative risk (RR), 0.56; 95% CI, 0.42–0.75; p < 0.0001; I 2 = 0; high-certainty evidence). Antifibrotic therapy did not significantly decrease all-cause mortality (nine trials with 1990 subjects; RR, 0.76; 95% CI, 0.55–1.03; p = 0.08; I 2 = 0; low-certainty evidence). However, in patients with progressive fibrosing ILDs (PF-ILD), antifibrotic therapy decreased all-cause mortality (four trials with 1100 subjects; RR, 0.69; 95% CI, 0.48–0.98; p = 0.04; I 2 = 0; low-certainty evidence). Conclusion: Our study supports the use of antifibrotic agents in patients with PF-ILDs, which could slow disease progression and decrease all-cause mortality. Trial registration: This study protocol was registered with PROSPERO (registration number: CRD42023411272).

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1177/17534666241232561

Cites

35 of 35 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1. The flowchart of study selection.
Figure 1. The flowchart of study selection.CC BY-NC · PubMed Central
Figure 2. The relative risk of antifibrotic therapy on disease progression in patients with fibrosing interstitial lung diseases.
Figure 2. The relative risk of antifibrotic therapy on disease progression in patients with fibrosing interstitial lung diseases.CC BY-NC · PubMed Central
Figure 3. Subgroup analyses for the relative risk of disease progression. (a) The relative risk of antifibrotic therapy on disease progression in patients with progressive fibrosing interstitial lung diseases and non-progressive fibrosing interstitial lung diseases. (b) The relative risk of pirfenidone and nintedanib on disease progression in patients with fibrosing interstitial lung diseases.
Figure 3. Subgroup analyses for the relative risk of disease progression. (a) The relative risk of antifibrotic therapy on disease progression in patients with progressive fibrosing interstitial lung diseases and non-progressive fibrosing interstitial lung diseases. (b) The relative risk of pirfenidone and nintedanib on disease progression in patients with fibrosing interstitial lung diseases.CC BY-NC · PubMed Central
Figure 4. The relative risk of all-cause mortality in patients with fibrosing interstitial lung diseases who received antifibrotic therapy.
Figure 4. The relative risk of all-cause mortality in patients with fibrosing interstitial lung diseases who received antifibrotic therapy.CC BY-NC · PubMed Central
Figure 5. Subgroup analyses for the relative risk of all-cause mortality. (a) The relative risk of antifibrotic therapy on all-cause mortality in patients with progressive fibrosing interstitial lung diseases and non-progressive fibrosing interstitial lung diseases. (b) The relative risk of pirfenidone and nintedanib on all-cause mortality in patients with fibrosing interstitial lung diseases.
Figure 5. Subgroup analyses for the relative risk of all-cause mortality. (a) The relative risk of antifibrotic therapy on all-cause mortality in patients with progressive fibrosing interstitial lung diseases and non-progressive fibrosing interstitial lung diseases. (b) The relative risk of pirfenidone and nintedanib on all-cause mortality in patients with fibrosing interstitial lung diseases.CC BY-NC · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 35 references

Research works printed but not linked: 2

  1. Li T, 2016, Sci Rep, 6
  2. Campochiaro C, 2023, RMD, 9

Cited by

See all 15

Metadata

Authors
Li, D.-Y., Liu, X., Huang, J.-Y., Hang, W.-L., Yu, G.-R., & Xu, Y.
Affiliations
  • Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing, China
  • Nanjing University of Chinese Medicine (CN)
  • Shanghai University of Traditional Chinese Medicine (CN)
  • Department of Respiratory Medicine, Second Affiliated Hospital of Xuzhou Medical University, Xuzhou, China
Corresponding author
Xu, Yong
Venue
Therapeutic Advances in Respiratory Disease
Published
2024-01
Volume
18
Pages
17534666241232561-17534666241232561
ISSN
  • 1753-4658 (ISSN-L)
  • 1753-4666
OpenAlex
W4392249802
Cited by
15
References
35
Citations by year
2026: 5 · 2025: 8 · 2024: 2
FWCI
1.10
Type
journal article
Language
en
Open access
Locations
  • Therapeutic Advances in Respiratory Disease (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
Funders
NATCM’s Project of High-level Construction of Key TCM Disciplines
Topics
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Pulmonary Hypertension Research and Treatments
  • Health Sciences › Medicine › Rheumatology › Systemic Sclerosis and Related Diseases
Keywords
progressive fibrosing interstitial lung disease, nintedanib, pirfenidone, disease progression, all-cause mortality, acute exacerbation, idiopathic pulmonary fibrosis
MeSH terms
Antifibrotic Agents, Fibrosis, Humans, Prospective Studies, Randomized Controlled Trials as Topic, Lung Diseases, Interstitial, Disease Progression, Idiopathic Pulmonary Fibrosis

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Impact of antifibrotic therapy on disease progression, all-cause mortality, and risk of acute exacerbation in non-IPF fibrosing interstitial lung diseases: evidence from a meta-analysis of randomized controlled trials and prospective controlled studies. https://app.cochat.ai/papers/10.1177/17534666241232561
The paper
Li, D.-Y., Liu, X., Huang, J.-Y., Hang, W.-L., Yu, G.-R., & Xu, Y. (2024). Impact of antifibrotic therapy on disease progression, all-cause mortality, and risk of acute exacerbation in non-IPF fibrosing interstitial lung diseases: evidence from a meta-analysis of randomized controlled trials and prospective controlled studies. Therapeutic Advances in Respiratory Disease. https://doi.org/10.1177/17534666241232561

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.